Analyst Price Target is $62.60
▲ +89.93% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for DICE Therapeutics in the last 3 months. The average price target is $62.60, with a high forecast of $77.00 and a low forecast of $38.00. The average price target represents a 89.93% upside from the last price of $32.96.
Current Consensus is
The current consensus among 11 investment analysts is to buy stock in DICE Therapeutics.
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.